Skip to Main Content

Author Details

Maarten J IJzerman
Technical Medical Centre, University of Twente
1997
271
44
PMIDPaper TitleJournal TitlePublished Year
37608228Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia.Appl Health Econ Health Policy2024
37545289Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.Tumour Biol2024
36701982A systematic review of methodological considerations in time to diagnosis and treatment in colorectal cancer research.Cancer Epidemiol2023
37964874Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach.Front Pharmacol2023
37528204The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose-response meta-analysis.Br J Cancer2023
35583252Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis.Rheumatology (Oxford)2023
37351802Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.Pharmacoeconomics2023
37421156An evidence-base for the implementation of hospital-based palliative care programs in routine cancer practice: A systematic review.Palliat Med2023
37202606What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.Clin Rheumatol2023
37434157Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?Pediatr Rheumatol Online J2023
36721219Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review.Cost Eff Resour Alloc2023
36914665Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours.Sci Rep2023
36541133Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?Expert Rev Pharmacoecon Outcomes Res2023
36670332Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.Pharmacoeconomics2023
33938161Costs of Hospital-Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System.Arthritis Care Res (Hoboken)2022
35680113Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence.J Cancer Policy2022
35350994Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.BMC Med Res Methodol2022
35410419Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.Pediatr Rheumatol Online J2022
35671919The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence.J Cancer Policy2022
35779937Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force.Value Health2022
36480778Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.JCO Precis Oncol2022
36443366A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.Sci Rep2022
36522664The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact.BMC Health Serv Res2022
36045377Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.Cost Eff Resour Alloc2022
35972781Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.Acta Oncol2022
35870932Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis.Pediatr Rheumatol Online J2022
36063280Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.Target Oncol2022
36254284Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer.Heliyon2022
35158410Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.Eur J Haematol2022
35152171Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes.Lung Cancer2022
35279769Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors.Support Care Cancer2022
34973103Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation.Eur Radiol2022
35031089Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer.Value Health2022
34906505Heterogeneity in how women value risk-stratified breast screening.Genet Med2022
35296282Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography.BMC Cancer2022
35322390Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study.Patient2022
34814677How to Realize the Benefits of Point-of-Care Testing at the General Practice: A Comparison of Four High-Income Countries.Int J Health Policy Manag2022
32273196Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?Eur Urol Focus2021
33910430Early technology assessment of using whole genome sequencing in personalized oncology.Expert Rev Pharmacoecon Outcomes Res2021
33493663Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.J Mol Diagn2021
33518027Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening.Value Health2021
33567163An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.Asia Pac J Clin Oncol2021
33618655A scoping review of studies using observational data to optimise dynamic treatment regimens.BMC Med Res Methodol2021
33813943Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy.Med Decis Making2021
34951592Genomic Health Literacy Interventions in Pediatrics: Scoping Review.J Med Internet Res2021
34948955Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future.Int J Environ Res Public Health2021
34461484Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians.ESMO Open2021
34838271Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.Value Health2021
34329625Cost of colorectal cancer care: sufficient to inform cancer policy?Lancet Gastroenterol Hepatol2021
34044840Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol.BMC Health Serv Res2021
  • 1 - 50 of 271

Recommended Authors

Viknesh Sounderajah
Imperial College NHS Healthcare Trust
Career Start Year 2015
Number of shared co-authors 0
Dominic King
Sandwell and West Birmingham NHS Trust
Career Start Year 2010
Number of shared co-authors 0
Jeff Round
Institute of Health Economics, University of Alberta
Career Start Year 2010
Number of shared co-authors 0
Mike Paulden
School of Public Health, University of Alberta
Career Start Year 2009
Number of shared co-authors 0
Benjamin P Geisler
Massachusetts General Hospital, Harvard Medical School
Career Start Year 2008
Number of shared co-authors 0
Mohammad Hassan Murad
Evidence Foundation
Career Start Year 2008
Number of shared co-authors 0
Zhen Wang
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 0
Rickey E Carter
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 0
Nicholas Mitsakakis
Institute of Health Policy Management and Evaluation, University of Toronto
Career Start Year 2003
Number of shared co-authors 0
Samuel S Wu
University of Florida
Career Start Year 2001
Number of shared co-authors 0
Per Olav Vandvik
Lovisenberg Diaconal Hospital
Career Start Year 1998
Number of shared co-authors 0
Craig R Ramsay
Health Services Research Unit, University of Aberdeen
Career Start Year 1998
Number of shared co-authors 0
Emily Beth Devine
University of Washington
Career Start Year 1997
Number of shared co-authors 0
Christopher McCabe
Queens University Belfast
Career Start Year 1996
Number of shared co-authors 3
Mireille Goetghebeur
School of Public Health, Universite de Montreal 1
Career Start Year 1995
Number of shared co-authors 1
Andrew Walker
University of California San Diego
Career Start Year 1995
Number of shared co-authors 0
George Tomlinson
University Health Network
Career Start Year 1994
Number of shared co-authors 0
Ben van Hout
University of Sheffield
Career Start Year 1993
Number of shared co-authors 0
Jason N Doctor
University of Southern California
Career Start Year 1992
Number of shared co-authors 0
Ewout W Steyerberg
Leiden University Medical Center
Career Start Year 1992
Number of shared co-authors 4
Chris L Pashos
Data Sciences Institute, Takeda Pharmaceuticals International Inc.
Career Start Year 1990
Number of shared co-authors 0
Anna N A Tosteson
Dartmouth Cancer Center
Career Start Year 1988
Number of shared co-authors 0
Mark S Roberts
School of Public Health, University of Pittsburgh
Career Start Year 1988
Number of shared co-authors 0
Tor D Tosteson
Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center
Career Start Year 1985
Number of shared co-authors 0
Benjamin Djulbegovic
Medical University of South Carolina
Career Start Year 1985
Number of shared co-authors 1
Myriam G M Hunink
13Center for Health Decision Sciences, Harvard T.H. Chan School of Public Health
Career Start Year 1984
Number of shared co-authors 1
Theodore G Ganiats
university of california san diego
Career Start Year 1983
Number of shared co-authors 0
Mark Helfand
Oregon Health & Science University
Career Start Year 1983
Number of shared co-authors 0
Roger B Davis
Beth Israel Deaconess Medical Center
Career Start Year 1982
Number of shared co-authors 0
Barbara C Tilley
University of Texas Health Science Center, School of Public Health at Houston
Career Start Year 1977
Number of shared co-authors 0

Collaborators

Koen Degeling
Cancer Health Services Research, The University of Melbourne
Co-authored papers 23
Vishvanath Nene
International Livestock Research Institute (ILRI)
Co-authored papers 9
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 6
Amanda Pereira-Salgado
the University of Melbourne
Co-authored papers 4
Marliese Alexander
Department of Pharmacy, 5Peter MacCallum Cancer Centre
Co-authored papers 4
Niven Mehra
Radboud university medical center
Co-authored papers 3
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 3
Nathaniel D Osgood
University of Saskatchewan
Co-authored papers 3
Gavin M Wright
St. Vincent's Hospital, University of Melbourne
Co-authored papers 3
Michel J A M van Putten
Technical Medical Centre, Clinical Neurophysiology, University of Twente
Co-authored papers 3
James G Dolan
University of Rochester
Co-authored papers 2
Edwin Cuppen
Hartwig Medical Foundation
Co-authored papers 2
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 2
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Co-authored papers 2
Isabelle Soerjomataram
Erasmus MC University Medical Center
Co-authored papers 2
Susana Banerjee
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Co-authored papers 2
Clara Gaff
Murdoch Children's Research Institute
Co-authored papers 2
Arun A Azad
Peter MacCallum Cancer Centre
Co-authored papers 2
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 1
Elias Campo
Institute for Biomedical Research August Pi I Sunyer
Co-authored papers 1
Farwa Rizvi
Co-authored papers 1
Naveed Sattar
Co-authored papers 1
Kim N Chi
University of British Columbia
Co-authored papers 1
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 1
Sarah Wordsworth
Health Economics Research Centre, University of Oxford
Co-authored papers 1
Olivier Elemento
Meyer Cancer Center
Co-authored papers 1
Martijn P Lolkema
Erasmus MC Cancer Institute
Co-authored papers 1
James Buchanan
Health Economics Research Centre, University of Oxford
Co-authored papers 1
Liana Fraenkel
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Release 1.2